Induction Immunochemotherapy Followed by Hypo-Fractionated Radiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer
Clinical Lung Cancer · 2025
DOI: 10.1016/j.cllc.2025.01.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lung Cancer, 2025. Verfasst von Zihao Zhu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Fourth School of Clinical Medicine, Nan Jing Medical University, Nanjing, People's Republic of China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy, Chemoradiotherapy. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Jiangsu Cancer Hospital.
Abstract (Originalsprache)
PURPOSE: To evaluate the efficacy and safety of induction immunochemotherapy followed by hypo-fractionated radiotherapy (Hypo-RT) for locally advanced unresectable non-small cell lung cancer (LA-NSCLC). METHODS: This retrospective analysis involved the data of 35 patients with unresectable stage III LA-NSCLC receiving immunotherapy plus Hypo-RT from January 1, 2019, to December 31, 2023. At least 2 cycles of induction immunochemotherapy were initially administered, followed by a definitive Hypo-RT at 4 Gy per fraction. The primary endpoint was overall survival (OS) and the secondary endpoints were progression-free survival (PFS) and grade ≥ 3 nonhematologic toxicities. Time-to-event outcomes for the entire cohort were calculated using the Kaplan-Meier method. RESULTS: At a median follow-up of 31.5 months (95% confidence interval, 26.1 to 36.9 months), median OS did not reach, with 1, 2, and 3-year OS rates of 100.0%, 82.5%, and 77.3%, respectively. Disease progression or death was recorded in 18 (51.4%) patients, with a median PFS of 28.0 months (95% CI, 9.4 to 46.6 months). The 1, 2, and 3-year PFS rates were 74.3%, 55.7%, and 47.6%, respectively. CONCLUSION: Induction immunochemotherapy followed by Hypo-RT demonstrated promising efficacy and acceptable toxicity in patients with LA-NSCLC. Studies on Hypo-RT combined with induction and consolidation immunotherapies are warranted in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Fourth School of Clinical Medicine, Nan Jing Medical University, Nanjing, People's Republic of China.
- Department of Radiation Oncology, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, People's Republic of China.
- Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, People's Republic of China.
- Department of Medical Oncology, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, People's Republic of China.
- Department of Radiation Oncology, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, People's Republic of China. Electronic address: 1318294806…
Förderung
- Jiangsu Cancer Hospital
Zitieren
APA
Zhu, Z., Wu, J., Zhao, L., Jiang, N., Chen, Y., Song, X., Li, M., Jiang, M., Shi, M., Yu, S., Ren, B., Yin, R., Jiang, F., Wang, L., Kong, C., & Zhu, X. (2025). Induction Immunochemotherapy Followed by Hypo-Fractionated Radiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2025.01.012
Vancouver
Zhu Z, Wu J, Zhao L, Jiang N, Chen Y, Song X, et al. Induction Immunochemotherapy Followed by Hypo-Fractionated Radiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer. Clinical Lung Cancer. 2025. doi:10.1016/j.cllc.2025.01.012
BibTeX
@article{Zhu2025,
author = {Zhu, Zihao and Wu, Jianfeng and Zhao, Lijun and Jiang, Ning and Chen, Yu and Song, Xue and Li, Ming and Jiang, Ming and Shi, Meiqi and Yu, Shaorong and Ren, Binhui and Yin, Rong and Jiang, Feng and Wang, Li and Kong, Cheng and Zhu, Xiangzhi},
title = {Induction Immunochemotherapy Followed by Hypo-Fractionated Radiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer},
journal = {Clinical Lung Cancer},
year = {2025},
doi = {10.1016/j.cllc.2025.01.012}
}
EUVIMED